Literature DB >> 33963368

Prediction of 90-day mortality after surgery for colorectal cancer using standardized nationwide quality-assurance data.

R P Vogelsang1, R D Bojesen1,2, E R Hoelmich1, A Orhan1, F Buzquurz1, L Cai1, C Grube1, J A Zahid1, E Allakhverdiiev1,3, H H Raskov1, I Drakos1, N Derian1, P B Ryan4,5, P R Rijnbeek6, I Gögenur1,7.   

Abstract

BACKGROUND: Personalized risk assessment provides opportunities for tailoring treatment, optimizing healthcare resources and improving outcome. The aim of this study was to develop a 90-day mortality-risk prediction model for identification of high- and low-risk patients undergoing surgery for colorectal cancer.
METHODS: This was a nationwide cohort study using records from the Danish Colorectal Cancer Group database that included all patients undergoing surgery for colorectal cancer between 1 January 2004 and 31 December 2015. A least absolute shrinkage and selection operator logistic regression prediction model was developed using 121 pre- and intraoperative variables and internally validated in a hold-out test data set. The accuracy of the model was assessed in terms of discrimination and calibration.
RESULTS: In total, 49 607 patients were registered in the database. After exclusion of 16 680 individuals, 32 927 patients were included in the analysis. Overall, 1754 (5.3 per cent) deaths were recorded. Targeting high-risk individuals, the model identified 5.5 per cent of all patients facing a risk of 90-day mortality exceeding 35 per cent, corresponding to a 6.7 times greater risk than the average population. Targeting low-risk individuals, the model identified 20.9 per cent of patients facing a risk less than 0.3 per cent, corresponding to a 17.7 times lower risk compared with the average population. The model exhibited discriminatory power with an area under the receiver operating characteristics curve of 85.3 per cent (95 per cent c.i. 83.6 to 87.0) and excellent calibration with a Brier score of 0.04 and 32 per cent average precision.
CONCLUSION: Pre- and intraoperative data, as captured in national health registries, can be used to predict 90-day mortality accurately after colorectal cancer surgery.
© The Author(s) 2021. Published by Oxford University Press on behalf of BJS Society Ltd.

Entities:  

Mesh:

Year:  2021        PMID: 33963368      PMCID: PMC8105588          DOI: 10.1093/bjsopen/zrab023

Source DB:  PubMed          Journal:  BJS Open        ISSN: 2474-9842


Introduction

Improvements in 30-day mortality rates have made surgery for colorectal cancer (CRC) a feasible treatment option for the majority of patients despite an increase in baseline risk of patients. However, recent studies have questioned the appropriateness of 30-day mortality as a quality metric of CRC surgery, as mortality rates nearly double at 90 days. Accurate identification of distinct patient trajectories could facilitate early risk stratification, target clinical interventions and optimize care pathways to improve outcomes. Prediction of 90-day mortality could be a useful tool for tailoring postoperative treatment and surgical care. Recent advances in data science have challenged the boundaries of conventional clinical decision making and personalized risk profiling,. Individualized risk assessment provides opportunities for tailoring treatment strategies, optimizing healthcare resources and improving outcomes,. Data sources often differ by design, purpose and coding, limiting utilization in clinical practice,. Harmonization of data structures and vocabularies enables standardized analytical tools to be developed, that have proven efficient in producing reliable, transparent and reproducible patient-level risk-prediction models,. This study aimed to develop and standardize a multivariable patient-level model for prediction of 90-day mortality after CRC surgery, utilizing supervised machine learning on standardized nationwide CRC quality-assurance data.

Methods

Data sources

Data were acquired from the Danish Colorectal Cancer Group (DCCG.dk) database via a formal application from the Danish National Clinical Registry (www.rkkp.dk). This is a nationwide database containing information on all patients diagnosed with primary CRC in Denmark since 1 May 2001. A full description of the data source is provided in .

Target population

The target population was defined as all patients with a diagnosis of CRC undergoing major curative surgery in Denmark between 1 January 2004 and 31 December 2015. A complete list of the surgical procedures included in the study is available in . Patients undergoing palliative or intended compromised surgery were excluded, as were those diagnosed with CRC who died on the day of surgery. CRC was defined as adenocarcinoma of the colon or rectum, including histological subtypes.

Outcome

The outcome was all-cause mortality, with a time at risk of 90 days. All patients experienced the outcome of interest before 90 days of follow-up or contributed with at least 90 days of follow-up after surgery. No patients were lost to follow-up. The modelling index (t = 0) was set to postoperative day 1 to be able to include pre- and intraoperative variables in a surgical ‘gloves-off’ design targeting postoperative patient-level risk prediction.

Predictors

Pre- and intraoperative variables were obtained from the DCCG.dk including prior medical history within 10 years of CRC diagnosis. A description of the source variables is provided in Before analysis, all source variables were mapped to the Observational Medical Outcomes Partnership (OMOP) common vocabulary, using the SNOMED-CT, LOINC and CPT4 classification systems. After mapping, data were stored in a relational database structured according to the OMOP Common Data Model (CDM). Initial mapping from Danish source concepts to the OMOP common vocabulary was conducted by health taxonomy experts, using the Observational Health Data Science and Informatics (OHDSI) Natural Language Processing tools and manual curation. A multidisciplinary team of medical practitioners and data scientists performed quality control on the procedure mappings and evaluated the validity of links between source concepts and their equivalents in the OMOP common vocabulary. Granularity loss in the initial mappings was corrected by linking the source concepts with more precise terms from the OMOP common vocabulary. Where no equivalent could be found between source and OMOP concepts, the source concepts were populated in the CDM as custom concepts. Using the OHDSI Patient-Level Prediction framework, predictors were selected among pre- or intraoperative variables. A total of 121 OMOP concepts participated as potential predictors in the model-training process. All concepts were classified within the OMOP domains of gender, conditions, measurements, observations and procedures. All continuous numerical values were categorized, except for height and weight measurements. A full list of the OMOP predictors is provided in .

Missing data

Standard machine learning practice was followed, encoding the categorical variable classes using one-hot encoding (1-of-K encoding, binary encoding). During one-hot encoding, binary predictors were constructed for each variable class, indicating the presence or absence of the class in the source data. Thus, missing values were indicated in the CDM by the recorded absence of all classes for a single categorical variable. Missing values of two continuous numerical variables affected by missing data, height and weight were imputed by zero.

Statistical analysis

Data were randomly divided into two data sets, one for model training using 75 per cent of patients and one for model testing containing 25 per cent. A least absolute shrinkage and selection operator (LASSO) logistic regression model was then developed for the prediction of 90-day mortality. The variance was optimized by maximizing the out-of-sample likelihood by three-fold cross-validation in the training set. Model performance in terms of discrimination was assessed by area under the receiver operating characteristics curve (AUROC) and area under the precision recall curve (average precision). Model calibration was evaluated by inspection of a standard calibration plot. Calibration was performed by dividing patients into deciles based on the predicted risk. The average predicted risk was calculated and plotted against the observed risk. Finally, a linear model was fitted, and the intercept and slope calculated to give a summary of the model calibration. Model prediction accuracy was evaluated by the Brier score as a measure of distance between the actual outcome and the predicted probability assigned to the outcome for each observation. Brier scores range between 0.0 and 1.0 with low values being desirable. The model results were benchmarked versus a Gradient Boosting Machine (GBM) model using the same predictor variables. Reporting of this study was in adherence to the TRIPOD guidelines. No risk groups were prespecified, and no external or temporal validation was planned for this nationwide study. The Regional Data Protection Committee approved the study (REG-071-2018). Ethical approval was not required according to Danish law. ATLAS version 2.7.2 (OHDSI) was used for cohort definition and data analysis. ATLAS is an open source application developed as a part of OHDSI intended to provide a unified interface to patient level data and analytics. The analysis backend of ATLAS was R version 3.4.3 (R Foundation for Statistical Computing). R is a language and environment for statistical computing and graphics. R is available as Free Software under the terms of the Free Software Foundation’s GNU General Public License in source code form. The R Foundation is seated in Vienna, Austria and currently hosted by the Vienna University of Economics and Business. It is a registered association under Austrian law and active worldwide. The R Foundation can be contacted by e-mail to R-foundation at r-project.org or The R Foundation for Statistical Computing c/o Institute for Statistics and Mathematics Wirtschaftsuniversität Wien Welthandelsplatz 1 1020 Vienna, Austria. The R packages used in this study were: OhdsiRTools (version 1.7.0), Cyclops (version 2.0.2), and PatientLevelPrediction (version 3.0.5). OHDSI is a multi-stakeholder, interdisciplinary collaborative to bring out the value of health data through large-scale analytics. All solutions are open-source. OHDSI has established an international network of researchers and observational health databases with a central coordinating center housed at Columbia University. Packages were obtained from the OHDSI Methods Library (https://github.com/OHDSI). A full description of the standardized data science framework is available in .

Results

Participants

Data from 49 607 Danish patients were retrieved. After exclusions, 32 927 patients were included in the analysis (). Mean(s.d.) patient age was 70.3(10.5) years; 15 340 (46.6 per cent) were female; 20 756 (63 per cent) had no concurrent co-morbidities (Charlson Comorbidity Index 0); 30 112 (91.5 per cent) underwent elective surgery; and 17 659 (53.6 per cent) were operated by a minimally invasive technique. Death within 90 days of surgery occurred in 1754 (5.3 per cent) patients. Baseline characteristics by outcome status are summarized in Cohort definition Description of the study cohort, including cohort exclusions with reasons. The DCCG.dk cohort included all Danish patients registered in the nationwide Danish Colorectal Cancer Group (DCCG.dk) database with a diagnosis of colorectal cancer (CRC) between 1 January 2004 and 31 December 2015 Baseline characteristics of the study cohort Values in parentheses are percentages, except where indicated otherwise. *Values are mean(s.d.); †values are median (i.q.r.). ‡Non-smoker, never smoked tobacco; ex-smoker, smoking cessation for ≥8 weeks before surgery; current smoker, currently smoking. §Diagnoses of co-morbidity registered up to 10 years before colorectal cancer diagnosis. ¶Conversion from minimally invasive surgery to open surgery. Transfusion of any blood product during surgery. **Any iatrogenic injury during surgery to undefined anatomical structure, urinary bladder, the duodenum, the gallbladder, the colon, the liver, the spleen, the pancreas, the sacral nerves, the small intestine, the ureter, the urethra, the vagina or the ventricle. ††Rectal cancer, tumours located within 15 cm of the anal verge; colon cancer, tumours located more than 15 cm from the anal verge. ‡‡. §§Multidisciplinary team (MDT) was formally registered since 1 January 2010 (quality control indicator since 1 January 2014). TaTME, transanal total mesorectal excision; SEMS, self-expanding metal stent. Damage Control Surgery: Two-stage surgical procedure due to acute presentation.

Model development

The data set included 121 candidate predictors corresponding to 14.5 events per predictor variable. Utilizing the standardized OHDSI Patient-Level Prediction framework for model development and validation, the data were split into 24 695 training patients and 8231 test patients. The training set was further divided into three equally sized data sets of 8233, 8231 and 8231 patients to perform three-fold cross-validation for hyperparameter selection. The training and test data sets included 1316 and 438 outcome events, respectively. In total, 65 predictors were selected in the final model. Among the selected model co-variables, increasing age, smoking status, the combined co-morbidity status (Charlson Comorbidity index) and individual co-morbid conditions at time of surgery, such as cerebrovascular disease, chronic obstructive lung disease, heart failure and peripheral vascular disease, were more frequent among patients who died within 90 days of surgery. In addition, clinical factors associated with emergency surgery, including open surgery, tumour perforation and perioperative blood transfusion, were more frequent among patients who died within 90 days of surgery. A full description of the model predictors is provided in .

Model performance

The model's test-set AUROC was 85.3 (95 per cent c.i. 83.6 to 87.0) for prediction of 90-day mortality following surgery for colorectal cancer. The model showed excellent calibration with a Brier score of 0.04 and 0.32 average precision. The model discrimination characteristics are presented in , with age, gender and overall model calibrations in . The intercept of the linear model fitted on the calibration results was -0.00 with a calibration gradient of 1.04. Clinical model performance characteristics for identifying high- and low-risk patients are detailed in and . Model discrimination characteristics a Receiver operating characteristic curve for the least absolute shrinkage and selection operator regression model test set (n = 8231). Area under the receiver operating characteristic (AUROC) curve = 85.28 (95% c.i. 83.55 to 85.01). The false-positive rate is 1 – specificity. The diagonal line indicates the neutral predictive value (AUROC = 50.0). b Precision-recall plot with an area under the precision-recall curve of 31.40. Recall (sensitivity) and precision (positive predictive value) are shown on the x- and y-axes, respectively. The horizontal line indicates the neutral predictive value (positive predictive value of 5.3, i.e., average population risk of death). c F1 score versus prediction threshold for 90-day mortality after colorectal cancer surgery. The F1 score represents a balanced measure of overall classifier performance, combining both precision and recall with equal weights. The classifier performance of the model was optimal at model threshold of 0.2. d Model prediction score distribution. The prediction score distribution represents the predicted risk distribution for those with and without the outcome. The more these curves overlap, the worse the model discrimination performance Model calibration a Calibration plot for the least absolute shrinkage and selection operator regression model test set (n = 8231). Bars indicate 95% confidence intervals. Calibration gradient = 1.04. Intercept = -0.00. b Demographic calibration plots for across gender and age groups of 5-year intervals Model performance characteristics: identification of high-risk patients at various model thresholds Model risk threshold: continuous model coefficient scale ranging from 0.0–1.0. * Positive predictive value. Classification of high-risk patients with an above-average risk of 90-day mortality according to specific model risk threshold settings. The average population risk of 90-day mortality after colorectal cancer surgery was 5.3%. Model performance characteristics: identification of low-risk patients at various model thresholds Model risk threshold: continuous model coefficient scale ranging from 0.0–1.0. *Negative predictive value. Classification of low-risk patients with a below-average risk of 90-day mortality according to specific model risk threshold settings. The average population risk of 90-day mortality after colorectal cancer surgery was 5.3%. The discriminatory performance of the GBM benchmark model was slightly lower with AUROC 84.63 (95 per cent c.i. 82.83 to 86.42). Calibration intercept was -0.00 and calibration gradient 1.04 with 0.04 Brier score and 0.32 average precision. The performance characteristics of the GBM model is presented in Figs S1 and S2.

Discussion

Based on nationwide CRC quality-assurance data, a supervised machine-learning model predicting 90-day mortality after CRC surgery was successfully developed and internally validated. The model was developed by adhering to the OMOP CDM and the OHDSI framework for data standardization and patient-level prediction resulting in high discriminatory power with AUROC of 85.28 per cent and excellent calibration with robust predictions across age and sex distributions. The model index was set on postoperative day 1, incorporating prior medical history and the intraoperative course of each patient into a postoperative ‘gloves-off’ prediction model. From a clinical perspective, many of the high-risk groups identified by the model have the potential to participate in personalized patient treatment. A characteristic example was the identification of 5.5 per cent of all patients undergoing CRC surgery who faced more than a 35 per cent risk of 90-day mortality, corresponding to a relative risk 6.7 times higher than the average population risk (5.3 per cent). The ability to personalize patients' risk and identify patients at high risk enables closer and prolonged observation in order to prevent complications, especially those that have the potential to result in death. Identification of such patients can also optimize healthcare-resource utilization, allowing more resources can be allocated for patients at high risk to ensure targeted rehabilitation and closer follow-up. Similarly, the patients identified as low risk can gain benefit by treatment personalization. For example, 20.9 per cent of patients identified by the model with low risk (0.3 per cent) of death within 90 days of CRC surgery, were facing 17.6 times decreased risk of death compared with the average risk of the CRC population. A patient with such a low-risk profile may benefit from tailored care, including early discharge or early referral to adjuvant chemotherapy when indicated. The standardized machine learning approach maximized the predictive accuracy of deep phenotypic, nationwide quality-assurance data for early postoperative prediction of mortality after CRC surgery. This approach contrasts with previous models targeting postoperative short-term outcome predictions by limited or intermediate sets of prespecified predictors. Limiting the number of predictor variables has been widely advocated to reduce model complexity and make models applicable in bedside clinical settings, but such approaches conflict with the current digital reality of clinical medicine, where patients generate abundant and potentially predictive data. Although the performance of the model may be considered high in terms of discriminatory power and calibration, the clinical interpretation of single underlying predictors, for instance open versus minimally invasive surgery, should be made with caution as they do not represent causal relationships per se. Modifying potentially reversible predictors or targeting postoperative interventions for high- or low-risk individuals should call for testing in randomized clinical trials. Previous models have primarily targeted prediction of mortality within 30 days after surgery; the most prominent being the Surgical Risk Calculator developed by the American College of Surgeons. The Surgical Risk Calculator model achieved a high accuracy with a C-index of 0.91 and Brier score 0.029 in predicting 30-day mortality by incorporating 21 preoperative predictor variables into the prediction model. Data from the American College of Surgeons National Surgical Quality Improvement Program is, however, limited by a short follow-up of only 30 days. Currently, models targeting 90-day mortality predictions after colorectal cancer surgery are scarce and do not target clinical use. This study has several limitations. Although using the full spectrum of readily available quality-assurance data maximized the predictive power of the model, this also increased model complexity. Integration of the prediction model directly into an electronic health record could provide clinicians with support for accurate postoperative patient-risk stratification and limit resources spent on collecting data for real-time clinical applications. The model was derived from a nationwide patient cohort, including data on all patients diagnosed with CRC in Denmark. As the data may be unique to the Danish CRC setting, external validation should be performed, to see if these findings can be generalized to other countries. This external validation would also determine if the discriminatory power of this model was robust for populations and data-capture processes in other healthcare systems, so that the extent of recalibration required to provide accurate predictions in these other contexts could be identified. The present study group aims to perform this validation within the European Health Data and Evidence Network (EHDEN) and the international OHDSI community by conducting network studies. A significant limitation of most previous models includes considerable risk of spectrum bias. Using nationwide data from a quality-assurance registry containing more than 95 per cent of all CRC patients with data collected contemporaneously by the operating surgeon at each institution using a standardized web-based application, this risk is considered low for the present study. The model showed a tendency towards over-estimation in low- and high-probability female patients, reflecting the nature of the dataset that included only limited numbers of patients in both extremes of the age distribution. Of note, the model accurately predicted mortality outcomes in both sexes undergoing either acute or elective surgery for either colon or rectal cancer in individuals from 50 to 95 years of age. In general, the classification characteristics of the model showed a moderate average precision. A class imbalance may explain these findings in the dataset, which conferred the model to assign the majority non-outcome class higher weight. A feasible option for future studies would be to investigate the predictive power in external data sets and clinical trial settings to assess how transportable the model is to other data sets, populations and clinical practice. The model presented here was not intended to support clinical decision making during preoperative planning, but exclusively targeted postoperative risk prediction. The model provides accurate identification of high- and low-risk patients early in the postoperative period that can provide clinicians with a powerful tool for personalized patient trajectories and the opportunity to improve outcomes after surgery for CRC. Click here for additional data file.
Table 1

Baseline characteristics of the study cohort

CharacteristicStudy cohort (n = 32 927)MissingAlive 90 days after surgery (n = 31 173)Deceased within 90 days after surgery (n = 1754)
Demographic
Sex, female 15 340 (46.6)0 (0)14 563 (46.7)777 (44.3)
Age (years)* 70.3(10.5)069.9(10.4)79. (8.8)
Height (cm)* 170.83(9.4)4741(14.4)170.89(9.4)169.26(10.0)
Weight (kg)* 75.75(16.8)4596(14.0)75.92(16.8)71.61(17.7)
Smoking status 5693 (17.3)
  Non-smoker10 214 (37.5)9864 (37.7)350 (32.5)
  Ex-smoker11 533 (42.4)11 078 (42.4)455 (42.3)
  Current smoker5487 (20.2)5215 (19.9)272 (25.3)
Alcohol consumption 5568 (16.9)
  Consumer, 1–14 drinks/week16 176 (59.1)15 643 (59.5)533 (49.1)
  Consumer, 15–21 drinks/week2037 (7.45)1972 (7.5)65 (6.0)
  Consumer, >21 drinks/week1964 (7.2)1879 (7.2)85 (7.8)
  Non-consumer7182 (26.3)6779 (25.8)403 (37.1)
Clinical characteristics
ASA score 460 (1.4)
  I7418 (22.9)7316 (23.8)102 (5.9)
  II18 149 (55.9)17 496 (56.9)653 (38.1)
  III6516 (20.1)5683 (18.5)833 (48.5)
  IV368 (1.1)245 (0.8)123 (7.2)
  V16 (0.0)11 (0.0)5 (0.3)
Charlson Comorbidity Index 0 (0)
 020 756 (63.0)20 079 (64.4)677 (38.6)
 1-29124 (27.7)8438 (27.1)686 (39.1)
  ≥33047 (9.3)2656 (8.5)391 (22.3)
Co-morbidities§0 (0)
  Chronic obstructive lung disease2619 (8.0)2314 (7.4)305 (17.4)
  Dementia296 (0.9)230 (0.7)66 (3.8)
  Hemiplegia52 (0.2)44 (0.1)8 (0.5)
  Cerebrovascular disease2576 (7.8)2276 (7.3)300 (17.1)
  Peripheral vascular disease1465 (4.5)1297 (4.2)168 (9.6)
  Heart failure1424 (4.3)1214 (3.9)210 (12.0)
  Myocardial infarction1150 (3.5)1030 (3.3)120 (6.8)
  Secondary malignant disease373 (1.1)322 (1.0)51 (2.9)
  Widespread metastatic malignant disease589 (1.8)533 (1.7)56 (3.2)
  Liver disease, mild224 (0.7)196 (0.6)28 (1.6)
  Liver disease, moderate to severe63 (0.2)48 (0.2)15 (0.9)
  Diabetes mellitus without complications2733 (8.3)2513 (8.1)220 (12.5)
  Diabetes mellitus with complications1195 (3.6)1088 (3.5)107 (6.1)
  Renal insufficiency702 (2.1)581 (1.9)121 (6.9)
  Peptic ulcer1012 (3.1)902 (2.9)110 (6.3)
  Connective tissue disorder824 (2.5)759 (2.4)65 (3.7)
Surgical characteristics
Surgical urgency 5 (0.0)
  Emergency2810 (8.5)2321 (7.5)489 (27.9)
  Elective30 112 (91.5)28 847 (92.6)1265 (72.1)
Surgical approach 0 (0)
  Laparotomy15 299 (46.5)14 070 (45.1)1229 (70.1)
  Laparoscopy16 732 (50.8)16 227 (52.1)505 (28.8)
  TaTME106 (0.3)103 (0.3)3 (0.2)
  Robotic-assisted surgery821 (2.5)802 (2.6)19 (1.1)
Conversion of procedure 2068 (6.3)218 (0.7)1966 (6.4)102 (5.8)
Intraoperative blood loss 100 (50–300)892 (2.7)100 (50–300)250 (100–600)
Intraoperative blood transfusion # 5107 (15.6)110 (0.3)4424 (14.2)683 (39.1)
Intraoperative complications**1254 (6.2)12 828 (39.0)1134 (5.9)120 (13.9)
Tumour characteristics
Cancer type †† 0 (0)
  Colon22 140 (67.2)20 769 (66.6)1371 (78.2)
  Rectum10 787 (32.8)10 404 (33.4)383 (21.8)
Tumor perforation present 1675 (5.1)56 (0.2)1447 (4.7)228 (13.0)
Treatment characteristics
Preoperative oncological treatment 0 (0)
  Chemoradiationtherapy2545 (7.7)2497 (8.0)48 (2.7)
  Chemotherapy2854 (8.7)2772 (8.9)82 (4.7)
  Radiotherapy2460 (7.5)2408 (7.7)52 (3.0)
Preoperative surgical treatment 13 002 (39.5)
  SEMS1195 (6.0)1133 (5.9)62 (7.7)
  Damage-control surgery‡‡3 (0.0)0 (0)3 (0.4)
  Preoperative MDT assessment§§11 957 (61.4)13 449 (40.8)11 599 (62.1)358 (45.7)

Values in parentheses are percentages, except where indicated otherwise. *Values are mean(s.d.); †values are median (i.q.r.). ‡Non-smoker, never smoked tobacco; ex-smoker, smoking cessation for ≥8 weeks before surgery; current smoker, currently smoking. §Diagnoses of co-morbidity registered up to 10 years before colorectal cancer diagnosis. ¶Conversion from minimally invasive surgery to open surgery. Transfusion of any blood product during surgery. **Any iatrogenic injury during surgery to undefined anatomical structure, urinary bladder, the duodenum, the gallbladder, the colon, the liver, the spleen, the pancreas, the sacral nerves, the small intestine, the ureter, the urethra, the vagina or the ventricle. ††Rectal cancer, tumours located within 15 cm of the anal verge; colon cancer, tumours located more than 15 cm from the anal verge. ‡‡. §§Multidisciplinary team (MDT) was formally registered since 1 January 2010 (quality control indicator since 1 January 2014). TaTME, transanal total mesorectal excision; SEMS, self-expanding metal stent. Damage Control Surgery: Two-stage surgical procedure due to acute presentation.

Table 2

Model performance characteristics: identification of high-risk patients at various model thresholds

Model risk thresholdProportion of the patients flagged as high-risk by the model (%)SensitivitySpecificityRisk of 90-day mortality (%)*Relative risk compared with the population
0.5 0.67.199.760.811.4
0.45 0.910.099.657.910.9
0.4 1.313.599.353.610.1
0.35 2.017.698.947.89.0
0.3 2.823.598.444.88.4
0.25 3.829.097.640.77.7
0.2 5.536.796.335.76.7
0.15 8.345.093.728.75.4
0.1 14.060.388.623.04.3
0.05 28.179.579.515.02.8
0.025 48.592.253.910.11.9
0.01 79.198.622.06.61.2
0.005 95.899.84.45.51.0

Model risk threshold: continuous model coefficient scale ranging from 0.0–1.0. * Positive predictive value. Classification of high-risk patients with an above-average risk of 90-day mortality according to specific model risk threshold settings. The average population risk of 90-day mortality after colorectal cancer surgery was 5.3%.

Table 3

Model performance characteristics: identification of low-risk patients at various model thresholds

Model risk thresholdProportion of patients flagged as low-risk by the model (%)SpecificitySensitivityRisk of 90-day mortality (per cent)*Relative risk compared with the population
0.5 99.499.77.15.00.9
0.45 99.199.610.04.80.9
0.4 98.799.313.54.70.9
0.35 98.098.917.64.50.9
0.3 97.298.423.54.20.8
0.25 96.297.629.03.90.7
0.2 94.596.336.73.60.7
0.15 91.693.745.03.20.6
0.1 86.088.660.32.50.5
0.05 71.979.579.51.50.3
0.025 51.553.992.20.80.2
0.01 20.922.098.60.30.1
0.005 4.24.499.80.30.1

Model risk threshold: continuous model coefficient scale ranging from 0.0–1.0. *Negative predictive value. Classification of low-risk patients with a below-average risk of 90-day mortality according to specific model risk threshold settings. The average population risk of 90-day mortality after colorectal cancer surgery was 5.3%.

  30 in total

1.  An Apgar score for surgery.

Authors:  Atul A Gawande; Mary R Kwaan; Scott E Regenbogen; Stuart A Lipsitz; Michael J Zinner
Journal:  J Am Coll Surg       Date:  2006-12-27       Impact factor: 6.113

Review 2.  Model for risk adjustment of postoperative mortality in patients with colorectal cancer.

Authors:  K Walker; P J Finan; J H van der Meulen
Journal:  Br J Surg       Date:  2014-12-18       Impact factor: 6.939

Review 3.  Machine Learning in Medicine.

Authors:  Alvin Rajkomar; Jeffrey Dean; Isaac Kohane
Journal:  N Engl J Med       Date:  2019-04-04       Impact factor: 91.245

4.  The appropriateness of 30-day mortality as a quality metric in colorectal cancer surgery.

Authors:  Mohamed Abdelgadir Adam; Megan C Turner; Zhifei Sun; Jina Kim; Brian Ezekian; John Migaly; Christopher R Mantyh
Journal:  Am J Surg       Date:  2017-06-03       Impact factor: 2.565

5.  Improved survival of colorectal cancer in Denmark during 2001-2012 - The efforts of several national initiatives.

Authors:  Lene H Iversen; Anders Green; Peter Ingeholm; Kell Østerlind; Ismail Gögenur
Journal:  Acta Oncol       Date:  2016-02-09       Impact factor: 4.089

6.  Comparison of 30-day, 90-day and in-hospital postoperative mortality for eight different cancer types.

Authors:  R A M Damhuis; B P L Wijnhoven; P W Plaisier; W J Kirkels; R Kranse; J J van Lanschot
Journal:  Br J Surg       Date:  2012-06-20       Impact factor: 6.939

7.  Mortality after emergency treatment of colorectal cancer and associated risk factors-a nationwide cohort study.

Authors:  Thea Helene Degett; Susanne Oksbjerg Dalton; Jane Christensen; Jes Søgaard; Lene Hjerrild Iversen; Ismail Gögenur
Journal:  Int J Colorectal Dis       Date:  2018-10-16       Impact factor: 2.571

8.  Derivation and validation of a preoperative risk model for postoperative mortality (SAMPE model): An approach to care stratification.

Authors:  Luciana Cadore Stefani; Claudia De Souza Gutierrez; Stela Maris de Jezus Castro; Rafael Leal Zimmer; Felipe Polgati Diehl; Leonardo Elman Meyer; Wolnei Caumo
Journal:  PLoS One       Date:  2017-10-30       Impact factor: 3.240

9.  Evaluating the impact of prediction models: lessons learned, challenges, and recommendations.

Authors:  Teus H Kappen; Wilton A van Klei; Leo van Wolfswinkel; Cor J Kalkman; Yvonne Vergouwe; Karel G M Moons
Journal:  Diagn Progn Res       Date:  2018-06-12

10.  Development and validation of a prognostic model predicting symptomatic hemorrhagic transformation in acute ischemic stroke at scale in the OHDSI network.

Authors:  Qiong Wang; Jenna M Reps; Kristin Feeney Kostka; Patrick B Ryan; Yuhui Zou; Erica A Voss; Peter R Rijnbeek; RuiJun Chen; Gowtham A Rao; Henry Morgan Stewart; Andrew E Williams; Ross D Williams; Mui Van Zandt; Thomas Falconer; Margarita Fernandez-Chas; Rohit Vashisht; Stephen R Pfohl; Nigam H Shah; Suranga N Kasthurirathne; Seng Chan You; Qing Jiang; Christian Reich; Yi Zhou
Journal:  PLoS One       Date:  2020-01-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.